NovoCure Ltd.

As of September 12, 2025, NovoCure Ltd. has shifted to a bearish technical trend, with significant underperformance compared to the S&P 500, reflecting a year-to-date return of -56.38% versus the S&P 500's 12.22%.

As of July 29, 2021, NovoCure Ltd. is considered risky and overvalued due to its high Price to Book Value of 5.24, negative EV to EBIT and EV to EBITDA ratios, and a concerning ROCE of -190.50%, with a year-to-date return of -56.38% compared to the S&P 500's 12.22%.

As of October 15, 2023, NovoCure Ltd. is considered attractive and undervalued, with a P/E ratio of 25.3, compared to peers like Illumina (36.2) and Amgen (21.5), indicating a favorable valuation and strong stock performance relative to the Sensex.

As of May 16, 2025, the stock's technical trend is mildly bearish, indicated by bearish momentum from the weekly MACD and daily moving averages, despite a bullish monthly KST, reflecting overall weakness compared to the S&P 500.

As of March 2022, NovoCure Ltd.'s management team includes Executive Chairman William Doyle, CEO Asaf Danziger, Lead Independent Director William Vernon, and several Independent Directors: Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, and Martin Madden.

NovoCure Ltd. is a small-cap oncology company focused on developing cancer treatments using TTFields technology. As of March 2025, it reported net sales of $155 million and a net loss of $34 million.

As of Jun 18, NovoCure Ltd. has a market capitalization of 1,943.19 million, with net sales of 621.71 million and a net profit of -164.19 million over the latest four quarters.